Nuvation Bio (NUVB) Depreciation & Amortization (CF) (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Depreciation & Amortization (CF) of $536000.0 for Q1 2026, up 72.9% year-over-year from $310000.0 in Q1 2025, and down 0.56% quarter-over-quarter from $539000.0 in Q4 2025.
Nuvation Bio (NUVB) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Depreciation & Amortization (CF) for 7 consecutive years, with $536000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 72.9% year-over-year to $536000.0; the TTM figure through Mar 2026 stood at $2.0 million (up 110.16% YoY), while the FY2025 annual figure was $1.7 million, up 154.61% from the prior year.
- Depreciation & Amortization (CF) retreated to $536000.0 in Q1 2026 per NUVB's latest filing, from $539000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $539000.0 in Q4 2025 and bottomed at $33000.0 in Q4 2023.
- Historically, Depreciation & Amortization (CF) has averaged $197470.6 across 5 years, with a median of $58000.0 in 2024.
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) tumbled 32.65% — and 2024, when it soared 563.64%.
- Nuvation Bio's Depreciation & Amortization (CF) stood at $49000.0 in 2022, then sank by 32.65% to $33000.0 in 2023, then jumped by 563.64% to $219000.0 in 2024, then jumped by 146.12% to $539000.0 in 2025, then retreated by 0.56% to $536000.0 in 2026.
- Business Quant data shows NUVB's Depreciation & Amortization (CF) at $536000.0 in Q1 2026, $539000.0 in Q4 2025, and $534000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | 536,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 536,000.00 |
| Jun 30, 2026 | 536,000.00 |
| Mar 31, 2026 | 536,000.00 |
| Mar 31, 2026 | 536,000.00 |
| Dec 31, 2025 | 539,000.00 |
| Dec 31, 2025 | 539,000.00 |
| Sep 30, 2025 | 534,000.00 |
| Sep 30, 2025 | 534,000.00 |
| Jun 30, 2025 | 356,000.00 |
| Jun 30, 2025 | 356,000.00 |
| Mar 31, 2025 | 310,000.00 |
| Mar 31, 2025 | 310,000.00 |
| Dec 31, 2024 | 219,000.00 |
| Dec 31, 2024 | 219,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Jun 30, 2024 | 244,000.00 |
| Jun 30, 2024 | 244,000.00 |
| Mar 31, 2024 | 58,000.00 |
| Mar 31, 2024 | 58,000.00 |